All In Biotech

Free tool

FAERS Monitor: Unasyn

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050608 or its brand name (Unasyn, Ampicillin Sodium, Sulbactam Sodium). Reports on generic versions are filed under their own applications.

Reports

1,708

Serious

1,594

93% of reports

Hospitalization

869

Death reported

337

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pneumonia146
  • pyrexia129
  • dyspnoea88
  • diarrhoea80
  • pain77
  • rash75
  • drug ineffective65
  • vomiting64
  • sepsis63
  • nausea61
  • hepatic function abnormal59
  • hypotension59
  • anaemia54
  • anxiety54
  • interstitial lung disease52

Reports by year received

View as table
YearReports
2004104
2005105
200695
2007100
200890
200956
2010122
2011139
2012106
201351
201465
201579
201691
201766
201859
201950
202044
202158
202240
202368
202460
202531
202629

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,451 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatic function abnormalSignal5919.515.21,017
interstitial lung diseaseSignal5213.210.1577
sepsisSignal637.05.5317
pneumoniaSignal1465.64.8549
pyrexiaSignal1294.63.9365
hypotensionSignal593.62.8110
anaemiaSignal543.52.794
anxietySignal542.31.841
rashSignal752.11.744
dyspnoea881.91.639
vomiting641.71.317
pain771.51.215
diarrhoea801.51.214
nausea610.90.70
drug ineffective650.60.517

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.